title: Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma.
abstract: The principal aim of our study was to investigate the usefulness of serum protein and circulating mRNA of insulin-like growth factor-1 (IGF-1) as a diagnostic and prognostic tool in hepatocellular carcinoma (HCC). Fifty-four HCC patients and age- and sex-matched 20 healthy controls were enrolled into this study. Pretreatment serum IGF-1 and IGF-1 mRNA were determined by the solid-phase sandwich ELISA and quantitative RT-PCR method, respectively. The median age at diagnosis was 60 years, range 36-77 years; where majority of group were male (n = 48, 88.8%). All patients had cirrhotic history. Forty-six percent (n = 25) of patients had Child-Pugh score A, 30% (n = 16) had score B or C. All of the patients were treated with local therapies and none of them received sorafenib. The baseline serum IGF-1 mRNA levels were significantly higher in HCC patients than in the control group (p = 0.04), whereas no significant difference was observed for IGF-1 protein levels between the two group (p = 0.18). Patients with history of HBV infection, who were not treated, and who received multiple palliative treatment for HCC had higher serum IGF-1 mRNA levels (p = 0.03, 0.03, and 0.05, respectively). Poor performance status (p < 0.001), viral etiology of cirrhosis (p = 0.03), larger tumor size (p = 0.01), lower serum hemoglobin levels (p = 0.03), and not be treated for HCC (p = 0.001) related to worse survival. However, neither serum IGF-1 nor serum IGF-1 mRNA had significantly adverse effect on survival (p = 0.53 and 0.42, respectively).
authors.affiliation: Department of Medical Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey, drsenemkarabulut@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: Karabulut
authors.forename: D
authors.initials: D
authors.lastname: Duranyıldız
authors.forename: F
authors.initials: F
authors.lastname: Tas
authors.forename: U
authors.initials: U
authors.lastname: Gezer
authors.forename: F
authors.initials: F
authors.lastname: Akyüz
authors.forename: M
authors.initials: M
authors.lastname: Serilmez
authors.forename: E
authors.initials: E
authors.lastname: Ozgür
authors.forename: C T
authors.initials: CT
authors.lastname: Yasasever
authors.forename: S
authors.initials: S
authors.lastname: Vatansever
authors.forename: N F
authors.initials: NF
authors.lastname: Aykan
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D007334:Insulin-Like Growth Factor I